<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; OBJECTIVE: Diagnosis of lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) is based on bone marrow <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Immunophenotyping will make diagnosis more precise through analyzing the origin and differentiation status of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, which is necessary for treatment and prognosis prediction </plain></SENT>
<SENT sid="2" pm="."><plain>This study was to analyze the immunophenotypic characteristics of lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and NHL with bone marrow involvement using flow cytometry (FCM) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Bone marrow specimens from 112 patients with lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series </plain></SENT>
<SENT sid="4" pm="."><plain>Using CD45/SSC gating strategy, the samples were analyzed with 5 parameters (FSC, SSC, McAb1-<z:chebi fb="0" ids="37926">FITC</z:chebi>, McAb2-PE, CD45-<z:chebi fb="0" ids="4056">cytochrome</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In 45 cases of precursor B lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20 </plain></SENT>
<SENT sid="6" pm="."><plain>In 32 cases of precursor T lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR </plain></SENT>
<SENT sid="7" pm="."><plain>Of the 77 cases of precursor ALL/LBL, 28(36.4%) expressed myeloid-associated antigens, such as CD13 and CD33; 9 (20.0%) cases of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>/LBL coexpressed CD20 and CD34; 28(87.5%) cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>/LBL coexpressed cyCD3 and TdT </plain></SENT>
<SENT sid="8" pm="."><plain>Among the 35 cases of mature B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, 17 cases of <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) expressed CD5, CD19, CD20, and HLA-DR </plain></SENT>
<SENT sid="9" pm="."><plain>Among the 10 mature T-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, 5 cases of unspecialied peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> expressed CD56 and HLA-DR, CD4 or CD8 or CD7 </plain></SENT>
<SENT sid="10" pm="."><plain>Mature lymphoid system <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> didn't express early antigens, such as CD34 and TdT, but expressed myeloid-associated antigens, especially CD13 and CD33 </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Multiparameter FCM can not only provide data of cell lineage and differentiation status but also detect phenotypic aberrancies, which is helpful for <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> detecting </plain></SENT>
</text></document>